# Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

> **NCT01011166** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 81 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** IDX184
- **DRUG:** Placebo
- **BIOLOGICAL:** Peginterferon alfa-2a (Peg-IFN)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01011166
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011166, "Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01011166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*